HomeGeneticsConditionGABA-transaminase deficiency
Back to Condition
GABA-transaminase deficiency
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

GABA-transaminase deficiency

GABA-transaminase deficiency is a rare, severe brain disease beginning in infancy that causes recurrent seizures, developmental delays, and accelerated physical growth.

Overview

GABA-transaminase deficiency is a brain disease (encephalopathy) that begins in infancy. Children with this disorder have profoundly impaired development. Most do not achieve normal developmental milestones of infancy, such as following others' movement with their eyes or sitting unassisted. Individuals with this disorder usually do not survive past the first 2 years of life, but some live longer into childhood.

Symptoms and Clinical Features

Babies affected by this condition experience a range of severe neurological and physical symptoms, which include:

  • Recurrent seizures (epilepsy)
  • Uncontrolled limb movements (choreoathetosis)
  • Exaggerated reflexes (hyperreflexia)
  • Weak muscle tone (hypotonia)
  • Excessive sleepiness (hypersomnolence)
  • Accelerated linear growth (growing faster in length than usual)
  • Feeding problems and a failure to gain weight as quickly as expected (failure to thrive)

Frequency

GABA-transaminase deficiency is a very rare disorder. Only a small number of affected individuals have been described in the medical literature.

Causes and Risk Factors

The condition is caused by mutations in the ABAT gene, which provides instructions for making the GABA-transaminase enzyme. This enzyme is responsible for breaking down a brain chemical (neurotransmitter) called GABA when it is no longer needed.

GABA is an inhibitory neurotransmitter that normally helps slow down brain cell activity to prevent the brain from being overloaded with too many signals. Mutations in the ABAT gene lead to a shortage of functional GABA-transaminase enzyme. Consequently, GABA is not properly broken down, causing this neurotransmitter and another molecule called beta-alanine to accumulate abnormally in brain cells.

This accumulation alters the balance of neurotransmitters in the brain, leading to the characteristic neurological problems of the disorder. Additionally, excess GABA leads to the abnormal release of a protein necessary for the growth of the body's bones and tissues, resulting in accelerated linear growth.

Inheritance

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Other Names for This Condition

  • 4 alpha aminobutyrate transaminase deficiency
  • ABAT deficiency
  • GABA transaminase deficiency
  • GABA transferase deficiency
  • GABA-T deficiency
  • Gamma aminobutyrate transaminase deficiency
  • Gamma aminobutyric acid transaminase deficiency
  • Gamma-aminobutyrate transaminase deficiency
  • Gamma-aminobutyric acid transaminase deficiency

Frequently Asked Questions

Clinicians look for a combination of severe developmental delay, failure to achieve basic motor milestones (e.g., sitting or grasping), recurrent seizures that are resistant to standard antiepileptic drugs, and unusually rapid linear growth. If these features appear before 12 months, a metabolic work‑up including plasma and cerebrospinal fluid amino acid analysis, followed by genetic sequencing of the ABAT gene, is recommended.
Most children with GABA‑transaminase deficiency do not survive beyond the second year of life, but a minority may live into early childhood with intensive care. Parents should plan for frequent hospital visits, anticipate the need for long‑term seizure monitoring, and coordinate with a multidisciplinary team (neurology, genetics, nutrition, and palliative care). Early palliative care discussions can help set realistic goals and support emotional well‑being.
Seizure management often requires a multi‑drug regimen, sometimes including benzodiazepines, levetiracetam, or phenobarbital, and may benefit from ketogenic diet trials. Feeding support involves high‑calorie, nutrient‑dense formulas, and in some cases, gastrostomy tubes to ensure adequate nutrition. Regular monitoring by a neurologist, dietitian, and developmental specialist is crucial.
Research is exploring gene‑replacement strategies using viral vectors to restore functional ABAT enzyme, as well as small‑molecule inhibitors that reduce beta‑alanine accumulation. While these approaches are still experimental, families can inquire about ongoing clinical trials through rare disease registries or the NIH Rare Diseases Clinical Research Network.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA